Archives

  • 2026-02
  • 2026-01
  • 2025-12
  • 2025-11
  • 2025-10
  • 2023-07
  • 2023-06
  • 2023-05
  • 2023-04
  • 2023-03
  • 2023-02
  • 2023-01
  • 2022-12
  • 2022-11
  • 2022-10
  • 2022-09
  • 2022-08
  • 2022-07
  • 2022-06
  • 2022-05
  • 2022-04
  • 2022-03
  • 2022-02
  • 2022-01
  • 2021-12
  • 2021-11
  • 2021-10
  • 2021-09
  • 2021-08
  • 2021-07
  • 2021-06
  • 2021-05
  • 2021-04
  • 2021-03
  • 2021-02
  • 2021-01
  • 2020-12
  • 2020-11
  • 2020-10
  • 2020-09
  • 2020-08
  • 2020-07
  • 2020-06
  • 2020-05
  • 2020-04
  • 2020-03
  • 2020-02
  • 2020-01
  • 2019-12
  • 2019-11
  • 2019-10
  • 2019-09
  • 2019-08
  • 2019-07
  • 2019-06
  • 2019-05
  • 2019-04
  • 2018-11
  • 2018-10
  • 2018-07

    • EZ Cap™ Cy5 Firefly Luciferase mRNA (5-moUTP): Cap1-Cappe...

    2025-12-27

    EZ Cap™ Cy5 Firefly Luciferase mRNA (5-moUTP): Cap1-Capped, Fluorescently Labeled mRNA for Mammalian Expression

    Executive Summary: EZ Cap™ Cy5 Firefly Luciferase mRNA (5-moUTP) is a chemically modified mRNA optimized for mammalian translation, featuring enzymatic Cap1 capping and dual 5-methoxyuridine (5-moUTP)/Cy5 labeling for enhanced stability and visualization (APExBIO). The Cap1 structure improves translational efficiency and reduces innate immune activation compared to Cap0 (Tang & Hattori 2024). Cy5 incorporation allows fluorescence-based tracking while retaining luciferase activity for bioluminescent assays. 5-moUTP modification further stabilizes the mRNA and suppresses immune sensing. This dual-mode reporter is validated in vitro and in vivo for mRNA delivery, translation efficiency, and imaging (Tang & Hattori 2024).

    Biological Rationale

    mRNA-based reporters are essential for quantifying delivery, translation, and expression efficiency in mammalian systems (Tang & Hattori 2024). Wild-type mRNA triggers innate immune responses and exhibits rapid degradation due to RNase activity and immune sensing by pattern recognition receptors (Tang & Hattori 2024). Cap1 capping and nucleotide modifications, such as 5-moUTP, mitigate these challenges by reducing immunogenicity and enhancing translation. Fluorescent labeling (e.g., Cy5) enables direct tracking of mRNA uptake and biodistribution, crucial for delivery optimization and mechanistic studies (Related Review). EZ Cap™ Cy5 Firefly Luciferase mRNA (5-moUTP) integrates these features, providing a dual-mode tool for advanced mRNA research.

    Mechanism of Action of EZ Cap™ Cy5 Firefly Luciferase mRNA (5-moUTP)

    This product encodes firefly luciferase from Photinus pyralis, which, after translation in mammalian cells, catalyzes the ATP-dependent oxidation of D-luciferin, emitting light near 560 nm (Tang & Hattori 2024). The mRNA features a Cap1 structure added enzymatically using Vaccinia virus Capping Enzyme (VCE), GTP, S-adenosylmethionine (SAM), and 2'-O-Methyltransferase, which ensures proper translation initiation and immune evasion (APExBIO). 5-moUTP incorporation at uridine positions reduces recognition by innate immune receptors (RIG-I, TLR7/8) (Tang & Hattori 2024). Cy5-UTP is incorporated in a 3:1 ratio with 5-moUTP, providing a red-shifted fluorescent signal (excitation 650 nm, emission 670 nm) for live-cell and in vivo tracking. The poly(A) tail enhances stability and translation efficiency. The mRNA is supplied at ~1 mg/mL in 1 mM sodium citrate buffer, pH 6.4, and is compatible with standard mRNA transfection protocols.

    Evidence & Benchmarks

    • Cap1-capped, 5-moUTP-modified mRNA shows increased translation efficiency and reduced immune activation in HeLa and HepG2 cells, with up to 2.7-fold increased luciferase activity after 24 h transfection (Tang & Hattori 2024).
    • Cy5-labeled mRNA lipoplexes accumulate in lungs after intravenous injection in mice, enabling visualization of tissue biodistribution (Tang & Hattori 2024).
    • Firefly luciferase mRNA exhibits high signal-to-background ratios in both in vitro and in vivo reporter gene assays (Internal Review).
    • Poly(A) tail and chemical modifications extend mRNA half-life and improve translation initiation efficiency (Internal Analysis).
    • APExBIO's R1010 product is validated for research use in mRNA delivery, translation efficiency assays, cell viability studies, and in vivo imaging (APExBIO).

    Applications, Limits & Misconceptions

    EZ Cap™ Cy5 Firefly Luciferase mRNA (5-moUTP) is designed for:

    • mRNA delivery benchmarking: Quantitative assessment of delivery vehicles (lipoplexes, LNPs) via fluorescence and bioluminescence (Tang & Hattori 2024).
    • Translation efficiency assays: Direct measurement of protein synthesis from delivered mRNA in mammalian cells and tissues.
    • In vivo imaging: Real-time tracking of mRNA biodistribution and expression using Cy5 fluorescence and luciferase bioluminescence.
    • Cell viability and immune activation studies: Evaluation of mRNA-induced cytotoxicity and innate immune responses in different cell types.

    For a mechanistic exploration of these advances, see this article, which details the interplay of chemical modifications and the dual-reporter approach. This dossier extends that coverage by integrating recent in vivo benchmarks and practical workflow parameters.

    Common Pitfalls or Misconceptions

    • Not for therapeutic use: This product is intended for research only; it is not approved for human or veterinary therapy (APExBIO).
    • Does not bypass all immune sensing: While 5-moUTP and Cap1 modifications reduce immune activation, some cell types may still mount responses under certain conditions (Tang & Hattori 2024).
    • Fluorescence may not reflect translation: Cy5 signal indicates mRNA presence, not necessarily successful translation or protein expression.
    • Product stability is temperature-sensitive: Storage above -40°C or repeated freeze-thaw cycles can degrade mRNA integrity and performance.
    • Not suitable for non-mammalian systems: Cap1 and poly(A) optimizations specifically enhance mammalian expression; effects may differ in other organisms.

    For further clarification on performance boundaries, see this recent analysis, which discusses limits of mRNA stability and immune evasion.

    Workflow Integration & Parameters

    The R1010 kit is supplied at ~1 mg/mL in 1 mM sodium citrate buffer, pH 6.4. Optimal storage is at -40°C or below. Thaw on ice and protect from RNase contamination. Typical applications include:

    • Transfection of mammalian cell lines using cationic lipids (e.g., DC-1-16/DOPE/PEG-Chol liposomes as in Tang & Hattori 2024).
    • In vivo administration via intravenous injection for tissue biodistribution and imaging studies.
    • Detection of Cy5 fluorescence (Ex 650 nm/Em 670 nm) for mRNA tracking and luciferase bioluminescence (560 nm) for translation readout.
    • Quantitative assays of translation efficiency and immune activation in parallel.

    For expanded workflow strategies, this guide explores advanced analysis of nanoparticle delivery and protein corona effects, which this article updates by focusing on dual-mode detection and immune suppression benchmarks.

    Conclusion & Outlook

    EZ Cap™ Cy5 Firefly Luciferase mRNA (5-moUTP) by APExBIO offers a robust, validated solution for dual-mode reporter assays in mammalian research. Its Cap1 capping, 5-moUTP modification, and Cy5 labeling meet current demands for efficient, low-immunogenicity, and highly trackable mRNA delivery (product page). Limitations include research-only usage and context-dependent immune responses. Future developments may further extend this platform’s capabilities for multiplexed detection and therapeutic research.